$PRPH
ProPhase Labs, Inc. Stock $prph

$prph Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000086827823000004 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$19.30M	$21.82M	$122.6M
YoY Change	-59.39%	-51.67%	55.17%
Cost Of Revenue	$8.783M	$10.54M	$51.99M
YoY Change	-53.42%	-48.68%	40.32%
Gross Profit	$10.52M	$11.28M	$70.65M
YoY Change	-63.32%	-54.17%	68.27%
Gross Profit Margin	54.5%	51.7%	57.61%
Selling, General & Admin	$8.298M	$12.74M	$34.39M
YoY Change	6.06%	63.78%	52.87%
% of Gross Profit	78.88%	112.93%	48.67%
Research & Development	$144.0K	$478.0K	$700.0K
YoY Change	311.43%	359.62%	34.62%
% of Gross Profit	1.37%	4.24%	0.99%
Depreciation & Amortization	$1.292M	$926.0K	$4.718M
YoY Change	3.44%	-22.18%	45.89%
% of Gross Profit	12.28%	8.21%	6.68%
Operating Expenses	$9.645M	$16.37M	$47.06M
YoY Change	-23.03%	49.65%	46.2%
Operating Profit	$875.0K	-$5.090M	$23.60M
YoY Change	-94.58%	-137.22%	140.74%
Interest Expense	$215.0K	-$99.00K	$764.0K
YoY Change	-191.1%	-67.65%	-202.41%
% of Operating Profit	24.57%		3.24%
Other Income/Expense, Net	-$107.0K	$0.00	$0.00
YoY Change	40.79%	-100.0%	-100.0%
Pretax Income	$564.0K	-$5.189M	$22.91M
YoY Change	-96.46%	-153.93%	331.82%
Income Tax	$14.00K	-$2.745M	$4.445M
% Of Pretax Income	2.48%		19.4%
Net Earnings	$550.0K	-$2.444M	$18.46M
YoY Change	-95.6%	-123.08%	194.32%
Net Earnings / Revenue	2.85%	-11.2%	15.05%
Basic Earnings Per Share	$0.03		$1.17
Diluted Earnings Per Share	$0.03	-$0.15	$1.02
COMMON SHARES
Basic Shares Outstanding	17.18M shares	16.28M shares	15.85M shares
Diluted Shares Outstanding	18.06K shares		18.65M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.56M	$17.44M	$17.44M
YoY Change	-46.99%	1.01%	1.01%
Cash & Equivalents	$9.613M	$9.109M	$9.109M
Short-Term Investments	$5.946M	$8.329M	$8.328M
Other Short-Term Assets	$3.573M	$2.366M	$2.366M
YoY Change	95.14%	35.51%	35.51%
Inventory	$4.311M	$3.976M	$3.976M
Prepaid Expenses
Receivables	$37.84M	$37.05M	$37.05M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$61.28M	$60.83M	$60.83M
YoY Change	-15.54%	-0.79%	-0.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.891M	$7.288M	$11.35M
YoY Change	-17.36%	22.55%	9.64%
Goodwill	$5.231M	$5.709M
YoY Change		0.0%
Intangibles	$14.52M	$8.475M
YoY Change		-21.9%
Long-Term Investments
YoY Change
Other Assets	$1.163M	$1.163M	$1.284M
YoY Change	133.07%	91.28%	20.22%
Total Long-Term Assets	$34.10M	$26.82M	$26.82M
YoY Change	25.77%	-4.16%	-4.16%
TOTAL ASSETS
Total Short-Term Assets	$61.28M	$60.83M	$60.83M
Total Long-Term Assets	$34.10M	$26.82M	$26.82M
Total Assets	$95.37M	$87.65M	$87.65M
YoY Change	-4.31%	-1.84%	-1.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.866M	$5.905M	$5.905M
YoY Change	-40.69%	-15.96%	-15.96%
Accrued Expenses	$802.0K	$714.0K	$3.481M
YoY Change	-77.16%	138.0%	-27.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.47M	$16.08M	$16.08M
YoY Change	-6.59%	3.55%	3.55%
LONG-TERM LIABILITIES
Long-Term Debt	$2.400M	$2.400M	$2.400M
YoY Change	-70.06%	-76.1%	-76.1%
Other Long-Term Liabilities	$14.57M	$5.318M	$5.318M
YoY Change	191.79%	4.21%	4.21%
Total Long-Term Liabilities	$16.97M	$7.942M	$7.718M
YoY Change	30.44%	-47.55%	-49.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.47M	$16.08M	$16.08M
Total Long-Term Liabilities	$16.97M	$7.942M	$7.718M
Total Liabilities	$35.43M	$24.02M	$24.02M
YoY Change	6.66%	-21.68%	-21.68%
SHAREHOLDERS EQUITY
Retained Earnings	$12.30M	$11.75M
YoY Change		344.85%
Common Stock	$17.00K	$16.00K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$59.94M	$63.63M	$63.63M
YoY Change
Total Liabilities & Shareholders Equity	$95.37M	$87.65M	$87.65M
YoY Change	-4.31%	-1.84%	-1.84%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$550.0K	-$2.444M	$18.46M
YoY Change	-95.6%	-123.08%	194.32%
Depreciation, Depletion And Amortization	$1.292M	$926.0K	$4.718M
YoY Change	3.44%	-22.18%	45.89%
Cash From Operating Activities	$476.0K	$811.0K	$28.60M
YoY Change	-97.65%	-117.45%	-310.0%
INVESTING ACTIVITIES
Capital Expenditures	$3.421M	$1.596M	$3.919M
YoY Change	-412.42%	5811.11%	-192.63%
Acquisitions	$2.904M		$0.00
YoY Change			-100.0%
Other Investing Activities	$1.769M	-$3.407M	$1.842M
YoY Change	-65.84%	-162.43%	-111.93%
Cash From Investing Activities	-$1.652M	-$5.003M	-$2.077M
YoY Change	-140.45%	-191.23%	-89.44%
FINANCING ACTIVITIES
Cash Dividend Paid	$0.00		$9.353M
YoY Change	-100.0%		105.74%
Common Stock Issuance & Retirement, Net			$2.152M
YoY Change			-94.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.680M	-9.498M	-$26.02M
YoY Change	-123.26%	887.32%	-174.08%
NET CHANGE
Cash From Operating Activities	$476.0K	811.0K	$28.60M
Cash From Investing Activities	-$1.652M	-5.003M	-$2.077M
Cash From Financing Activities	$1.680M	-9.498M	-$26.02M
Net Change In Cash	$504.0K	-13.69M	$451.0K
YoY Change	-97.06%	10852.0%	-75.52%
FREE CASH FLOW
Cash From Operating Activities	$476.0K	$811.0K	$28.60M
Capital Expenditures	$3.421M	$1.596M	$3.919M
Free Cash Flow	-$2.945M	-$785.0K	$24.68M
YoY Change	-113.77%	-83.2%	-362.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000868278
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	151728652	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17182841	shares
CY2022	dei	Auditor Name AuditorName	Morison Cogen LLP
CY2022	dei	Auditor Location AuditorLocation	Blue Bell, Pennsylvania
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9109000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8328000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	0	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	76000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37708000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4600000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1496000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61317000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7288000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5947000	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	460000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4402000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10852000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1163000	usd
CY2022Q4	us-gaap	Assets Assets	87648000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5905000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1009000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	99000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	301000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	663000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2499000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2034000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4190000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1312000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2072000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2495000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16075000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15524000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1059000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	905000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	224000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	44000	usd
CY2022Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	2400000	usd
CY2021Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	9996000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4259000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4198000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7942000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15143000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	24017000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30667000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16210776	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15485900	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109138000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104552000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	11753000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2642000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	18126970	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	16818846	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	58033000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	48407000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	757000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-175000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	63631000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58628000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87648000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89295000	usd
CY2022	us-gaap	Gross Profit GrossProfit	70654000	usd
CY2021	us-gaap	Gross Profit GrossProfit	41988000	usd
CY2022	prph	Diagnostic Expenses DiagnosticExpenses	12022000	usd
CY2021	prph	Diagnostic Expenses DiagnosticExpenses	9174000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34385000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22493000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	652000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	520000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	47059000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	32187000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	23595000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	9801000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	153000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	642000	usd
CY2022	us-gaap	Interest Expense InterestExpense	764000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1148000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-76000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-240000	usd
CY2022	prph	Impairment Of Secured Promissory Note Receivable ImpairmentOfSecuredPromissoryNoteReceivable	0	usd
CY2021	prph	Impairment Of Secured Promissory Note Receivable ImpairmentOfSecuredPromissoryNoteReceivable	3750000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22908000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5305000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-968000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6273000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	932000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-164000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19395000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6109000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15845000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15172000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18651000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18393000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	10556000	usd
CY2021	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	3000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	35135000	usd
CY2021	prph	Issuance Of Common Stock And Warrants For Cash From Private Offering IssuanceOfCommonStockAndWarrantsForCashFromPrivateOffering	5500000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3608000	usd
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	4546000	usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	917000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3183000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6273000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58628000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	600000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2152000	usd
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	9352000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7474000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	932000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3986000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	63631000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-354000	usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-165000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4718000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3234000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	343000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	329000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	127000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2022	prph	Impairment Of Secured Promissory Note Receivable ImpairmentOfSecuredPromissoryNoteReceivable	0	usd
CY2021	prph	Impairment Of Secured Promissory Note Receivable ImpairmentOfSecuredPromissoryNoteReceivable	3750000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3986000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3183000	usd
CY2022	prph	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	174000	usd
CY2021	prph	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	-240000	usd
CY2022	prph	Noncash Interest Income On Secured Promissory Note Receivable NoncashInterestIncomeOnSecuredPromissoryNoteReceivable	0	usd
CY2021	prph	Noncash Interest Income On Secured Promissory Note Receivable NoncashInterestIncomeOnSecuredPromissoryNoteReceivable	316000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-761000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3866000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	-78000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	267000	usd
CY2022	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	6163000	usd
CY2021	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4498000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38197000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-702000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1746000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	617000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1445000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	555000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	368000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1121000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2450000	usd
CY2022	prph	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	-881000	usd
CY2021	prph	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	1890000	usd
CY2022	prph	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances	-5000	usd
CY2021	prph	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances		usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	619000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2608000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	138000	usd
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes		usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-301000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	130000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	2878000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable		usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-423000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2827000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	28551000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13619000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9066000	usd
CY2022	prph	Issuance Of Secured Promissory Note Receivable IssuanceOfSecuredPromissoryNoteReceivable	0	usd
CY2021	prph	Issuance Of Secured Promissory Note Receivable IssuanceOfSecuredPromissoryNoteReceivable	1000000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6777000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	21527000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	7120000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1047000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	15858000	usd
CY2022	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	0	usd
CY2021	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	300000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	452000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3919000	usd
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4231000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2077000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19666000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	35135000	usd
CY2022	prph	Proceeds From Issuance Of Common Stock And Warrants From Private Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering	0	usd
CY2021	prph	Proceeds From Issuance Of Common Stock And Warrants From Private Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering	5500000	usd
CY2022	prph	Repurchase Of Common Stock For Payment Of Statutory Taxes Due On Cashless Exercise Of Stock Options RepurchaseOfCommonStockForPaymentOfStatutoryTaxesDueOnCashlessExerciseOfStockOptions	7474000	usd
CY2021	prph	Repurchase Of Common Stock For Payment Of Statutory Taxes Due On Cashless Exercise Of Stock Options RepurchaseOfCommonStockForPaymentOfStatutoryTaxesDueOnCashlessExerciseOfStockOptions	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7044000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	45000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2152000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	917000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	9353000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	4546000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-26023000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35127000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	451000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1842000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8658000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6816000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9109000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8658000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1696000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	763000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1000000	usd
CY2022	prph	Issuance Of Common Shares Related To Business Acquisition IssuanceOfCommonSharesRelatedToBusinessAcquisition	0	usd
CY2021	prph	Issuance Of Common Shares Related To Business Acquisition IssuanceOfCommonSharesRelatedToBusinessAcquisition	3608000	usd
CY2022	prph	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	600000	usd
CY2021	prph	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1294000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-164000	usd
CY2022	us-gaap	Goodwill Subsequent Recognition Of Deferred Tax Asset GoodwillSubsequentRecognitionOfDeferredTaxAsset	0	usd
CY2021	us-gaap	Goodwill Subsequent Recognition Of Deferred Tax Asset GoodwillSubsequentRecognitionOfDeferredTaxAsset	362000	usd
CY2022Q2	prph	Number Of Licensed Compounds NumberOfLicensedCompounds	2	numberoflicensedcompound
CY2022Q2	prph	Number Of Licensed Compounds NumberOfLicensedCompounds	2	numberoflicensedcompound
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business and Liquidity Risks and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our diagnostic service business is and will continue to be impacted by the level of demand for COVID-19 and other diagnostic testing, how long this demand persists, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services, as well as the availability of COVID-19 testing from other laboratories and the period of time for which we are able to serve as an authorized laboratory offering COVID-19 testing under various Emergency Use Authorizations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our revenues increased significantly for the year ended December 31, 2022 as a result of the diagnostic services business line, we have made and will continue to make substantial investments to secure the necessary equipment, supplies and personnel to provide these testing services. Our customer base for our COVID-19 tests is principally comprised of governmental bodies, municipalities, and large corporations who pay us directly or through third-party payers. While our revenues increased significantly since the launch of our diagnostic services business, we have been dependent on both government agency and insurance company reimbursement as well as the prevalence of COVID-19 associated strains.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), was enacted, providing for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. On March 22, 2022, the Health Resources & Services Administration (HRSA) program stopped accepting claims for COVID-19 testing and treatment due to lack of sufficient funds. As a result of the suspension of the HRSA uninsured program, we have not recognized any revenue related to COVID-19 testing that we performed for uninsured individuals from March 22, 2022 through December 31, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personal genomics business is and will continue to be influenced by demand for our genetic sequencing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracting manufacturing business is and will continue to be impacted by demand for our services, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consumer sales are and will continue to be impacted by (i) the timing of acceptance of our TK Supplements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for these products. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, $28.6 million was provided by operating activities. The Company had cash, cash equivalents and marketable securities of $17.4 million as of December 31, 2022. Based on management’s current business plans, the Company estimates that it will have enough cash and liquidity to finance its operating requirements for at least one year from the date of filing these financial statements. However, due to the nature of the diagnostic business and the Company's focus thus far on COVID-19, there are inherent uncertainties associated with managements’ business plan and cash flow projections if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services and to grow its other businesses.</span></div>As such, the Company’s future capital needs and the adequacy of its available funds will depend on many factors. These include, but not necessarily limited to, the actual cost and time necessary to achieve sustained profitability from diagnostic services, the ability to successfully diversify the diagnostic services revenue streams and the ability to market and grow the personal genomics, biopharma, manufacturing and supplement businesses. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Financial Risks</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and trade accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cash and cash equivalents with certain major financial institutions. As of December 31, 2022, our cash and cash equivalents and restricted cash balance was $9.1 million. Of the total bank balance, $1.0 million was covered by federal depository insurance and $8.4 million was uninsured at December 31, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depend on information provided and billing services of third parties. These credit concentrations impact our overall exposure to credit risk, which could be further affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of trade receivables and diagnostic test receivables. Additionally, the reimbursement receivables from the diagnostic service business are subject to billing errors and related disputes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also assess the financial condition of the debtor under our note receivable (see Note 13, Consulting Agreement and Secured Promissory Note Receivable and Consulting Agreement), balances due to us. As of December 31, 2022 and the financial statements reporting date, the Company did not expect full realization upon maturity.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, see Note 14 - Significant Customers Concentrations.</span></div>
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	28600000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	17400000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States of America (“GAAP”), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration around diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, sales returns and allowances, rates, slow moving, dated inventory and associated provisions, the estimated useful lives and potential impairment of long-lived assets, stock based compensation valuation, income tax asset valuations and assumptions related to accrued advertising.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></div>
CY2022Q4	us-gaap	Escrow Deposit EscrowDeposit	250000	usd
CY2021Q4	us-gaap	Escrow Deposit EscrowDeposit	250000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	7186000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1234000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	92000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8328000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8954000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	192000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8779000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	37568000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	18520000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2626000	usd
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	23089000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	40194000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	41609000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3140000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3901000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	37054000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	37708000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	5500000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3900000	usd
CY2022Q4	prph	Inventory Lab Material InventoryLabMaterial	1739000	usd
CY2021Q4	prph	Inventory Lab Material InventoryLabMaterial	2989000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1639000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1514000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	754000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	260000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	356000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	272000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	4488000	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	5035000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	512000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	435000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3976000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4600000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9100000	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1000000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	8400000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	8329000	usd
CY2022	prph	Revenue Recognition Subscriptions RevenueRecognitionSubscriptions	1000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3600000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2900000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	3500000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2499000	usd
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2034000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	683000	usd
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	530000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	376000	usd
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	375000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3558000	usd
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2939000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122647000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79042000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	700000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	500000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2939000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2642000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79042000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6273000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6109000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	81164000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	6135000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	901000	usd
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	4446000	usd
CY2021	prph	Adjustment For Deferred Tax Liability AdjustmentForDeferredTaxLiability	362000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12297000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12297000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3822000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1445000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8475000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10852000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1585000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1222000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1222000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	890000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	370000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3186000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8475000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15728000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12830000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8440000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6883000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7288000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5947000	usd
CY2022	us-gaap	Depreciation Depreciation	2300000	usd
CY2021	us-gaap	Depreciation Depreciation	1900000	usd
CY2022Q1	us-gaap	Cash Cash	1440548	usd
CY2022Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1400000	usd
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	40548	usd
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.75
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1150000	usd
CY2022Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2590548	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4700000	usd
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4600000	usd
CY2021	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2021Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4500000	usd
CY2021Q4	prph	Stock Issuance Costs Percent StockIssuanceCostsPercent	0.010
CY2021Q3	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P6M
CY2021	prph	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Granted Options Weighted Average Remaining Contractual Term2 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2022	prph	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Granted Options Weighted Average Remaining Contractual Term2 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageRemainingContractualTerm2	P7Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.03
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.29
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.79
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.79
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	2.5
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3952000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2961000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4500000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1833000	shares
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1040000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3543000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1318000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4583000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1318000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	72000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1511000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-210000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-775000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-138000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2286000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-968000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4811000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1232000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2789000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	366000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1200000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-601000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	227000	usd
CY2022	prph	Income Taxes From Continuing Operations Before Valuation Allowance IncomeTaxesFromContinuingOperationsBeforeValuationAllowance	5799000	usd
CY2021	prph	Income Taxes From Continuing Operations Before Valuation Allowance IncomeTaxesFromContinuingOperationsBeforeValuationAllowance	1825000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1354000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2793000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-968000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2022Q4	prph	Net Operating Loss And Capital Loss Carryforward NetOperatingLossAndCapitalLossCarryforward	1324000	usd
CY2021Q4	prph	Net Operating Loss And Capital Loss Carryforward NetOperatingLossAndCapitalLossCarryforward	3584000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1466000	usd
CY2021Q4	prph	Deferred Tax Asset Leasing Arrangements DeferredTaxAssetLeasingArrangements	1348000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2684000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2531000	usd
CY2022Q4	prph	Deferred Tax Assets Capital Lease Obligations DeferredTaxAssetsCapitalLeaseObligations	1466000	usd
CY2021Q4	prph	Deferred Tax Assets Capital Lease Obligations DeferredTaxAssetsCapitalLeaseObligations	-1348000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	705000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	948000	usd
CY2022Q4	prph	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	-2703000	usd
CY2021Q4	prph	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	-2989000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	824000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2178000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	224000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2200000	usd
CY2022Q4	prph	Tax Credit Carryforward Limitation Amount TaxCreditCarryforwardLimitationAmount	600000	usd
CY2022Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	1093000	usd
CY2021Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	1283000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	202000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	514000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	714000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	300000	usd
CY2022Q4	prph	Accrued Returns AccruedReturns	13000	usd
CY2021Q4	prph	Accrued Returns AccruedReturns	338000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	60000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2072000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2495000	usd
CY2021Q2	prph	Manufacturing Agreement Renewal Options ManufacturingAgreementRenewalOptions	5	periods
CY2021Q2	prph	Manufacturing Agreement Renewal Period ManufacturingAgreementRenewalPeriod	P1Y
CY2021Q2	prph	Agreement Term AgreementTerm	P90D
CY2022Q3	prph	Upfront License Fee UpfrontLicenseFee	50000	usd
CY2022Q3	prph	License Agreement Term LicenseAgreementTerm	P10D
CY2022Q3	prph	License Agreement Royalty Percent LicenseAgreementRoyaltyPercent	0.03
CY2022Q3	prph	License Agreement Minimum Royalty Obligation LicenseAgreementMinimumRoyaltyObligation	250000	usd
CY2020Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	4500	sqft
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4600000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	816000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	816000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	816000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	816000	usd
CY2022	us-gaap	Lease Cost LeaseCost	816000	usd
CY2021	us-gaap	Lease Cost LeaseCost	816000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	774000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	357000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	739000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	747000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	768000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	783000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	804000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3071000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6912000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2352000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4560000	usd
CY2022	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	0	usd
CY2021	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	642000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	0	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122600000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79000000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122647000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79042000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51993000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37054000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4542000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1983000	usd
CY2022	prph	Operating And Other Expenses OperatingAndOtherExpenses	43203000	usd
CY2021	prph	Operating And Other Expenses OperatingAndOtherExpenses	34700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22908000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5305000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-968000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6273000	usd
CY2022Q4	us-gaap	Assets Assets	87648000	usd
CY2021Q4	us-gaap	Assets Assets	89295000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	18464000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6273000	usd
CY2022	prph	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	632000	usd
CY2021	prph	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	1000000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	19096000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7273000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15845000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15172000	shares
CY2022	prph	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	1493000	shares
CY2021	prph	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	2001000	shares
CY2022	prph	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	1073000	shares
CY2021	prph	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	220000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	240000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1000000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18651000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18393000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1225000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1283000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005

Files In Submission

Name	View Source	Status
prph-20221231_cal.xml	Edgar Link	unprocessable
0000868278-23-000004-index-headers.html	Edgar Link	pending
0000868278-23-000004-index.html	Edgar Link	pending
0000868278-23-000004.txt	Edgar Link	pending
0000868278-23-000004-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fllpconsent-draft002.htm	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prophase-director2022plano.htm	Edgar Link	pending
prophase-exhibit21110xk2022.htm	Edgar Link	pending
prophase-exhibit311.htm	Edgar Link	pending
prophase-exhibit312.htm	Edgar Link	pending
prophase-exhibit321.htm	Edgar Link	pending
prophase-exhibit322.htm	Edgar Link	pending
prophase-formof2022planinc.htm	Edgar Link	pending
prophase-formof2022plannqo.htm	Edgar Link	pending
prophaselabs10kconsent_mc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prph-20221231.htm	Edgar Link	pending
prph-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
prph-20221231_lab.xml	Edgar Link	unprocessable
prph-20221231_pre.xml	Edgar Link	unprocessable
prph-20221231_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
prph-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRPH
ProPhase Labs, Inc. Stock $prph

2023 Q1 Form 10-K Financial Statement

#000086827823000004 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH ProPhase Labs, Inc. Stock $prph

2023 Q1 Form 10-K Financial Statement

#000086827823000004 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH
ProPhase Labs, Inc. Stock $prph